Medical weight loss at InjectCo MedSpa Cleburne is a medically supervised weight-management program that starts with clinical screening, not a prescription. If you qualify, a licensed prescriber supervised by our Medical Director, Dr. Josh Allen, D.O., may add medication such as semaglutide or tirzepatide as one part of the plan. The program is $425 a month.
Our med spa is at 424 W Henderson St in downtown Cleburne, Texas, a short walk east of H-E-B. Many visits can happen here or by video, so patients from Burleson, Joshua and Keene do not have to drive in for every check-in.
IMPORTANT: COMPOUNDED MEDICATION IS NOT FDA APPROVED
Some plans may include compounded semaglutide or compounded tirzepatide when a licensed prescriber decides a compounded preparation is appropriate for you. Compounded medications are not FDA-approved drugs and do not go through the FDA’s premarket review for safety, effectiveness or quality.
Before you start, your clinician should tell you exactly what product is prescribed, whether it is commercially manufactured or compounded, where it is dispensed from, and why that option is being considered.
When patients first ask about medical weight loss, the medication is often the part they know by name. Our job is to look at everything around it.
Before a prescription is considered, we review your health history, current medications, relevant testing and the reasons you are seeking treatment. Once you start, the conversation does not end with the prescription. At follow-up we want to know what has changed: appetite, side effects, hydration, bowel habits, eating patterns, whether you are taking every dose, and whether you are giving the medication correctly.
A higher dose is not automatically a better dose. If you are responding well and tolerating treatment, the right decision may be to stay where you are. If side effects are becoming a problem, the plan may need to change. And if medication is not appropriate, the safest decision may be not to prescribe it at all.
The prescription is one part of care. Monitoring what happens after that decision is what turns it into a medical program.
The prescriber. A licensed prescriber working under Dr. Josh Allen, D.O., InjectCo’s Medical Director, looks at your history and labs, decides whether to prescribe, and signs off on any dose change. Dr. Allen trained at Lake Erie College of Osteopathic Medicine and completed an emergency medicine residency with Texas A&M. You can check his NPI record (1982904033) and his license on the Texas Medical Board lookup.
Your check-in nurse. Paige, BSN, RN, runs check-ins every two weeks and passes what she finds to the prescriber. She does not prescribe or change doses. Before aesthetics, she spent six years in pediatric critical care. Nursing licenses can be checked on the Texas Board of Nursing lookup.
InjectCo runs nine Texas clinics, and Dr. Allen oversees protocols across all of them.
FDA-approved products are commercially manufactured semaglutide and tirzepatide that went through FDA review and carry an FDA label. Compounded preparations are made by a pharmacy or outsourcing facility. They are not FDA-approved, they are not generic versions of the approved brands, and the FDA has not reviewed them for equivalence. In the FDA’s words, compounded drugs “should only be used in patients whose medical needs cannot be met by an FDA-approved drug” (FDA).
When a compounded preparation is prescribed for a Cleburne patient, it is dispensed by a 503B outsourcing facility. Outsourcing facilities register with the FDA, but registration is not FDA approval or licensure of the facility or of its products. The facility’s name is on your prescription label, and you can look it up on the FDA’s list of registered outsourcing facilities.
As of September 25, 2026, the FDA lists neither semaglutide nor tirzepatide on its drug shortage list or its 503B bulks list. In April 2026 the FDA proposed excluding both from the 503B bulks list, and its compounding policy page still shows that as a proposal. If you are prescribed compounded semaglutide, ask whether it is made with semaglutide base. The FDA says semaglutide sodium and semaglutide acetate are different active ingredients and that it knows of no lawful basis for compounding with them.
Compounded injectable concentrations can vary between products. Measure only with the syringe that came with your prescription, and follow its instructions. Never borrow a dose from someone else’s plan, and never turn milligrams into syringe “units” with an online chart. The FDA has received reports of dosing errors with compounded semaglutide, some needing hospital care (FDA alert).
If your medicine comes in a multi-dose vial, follow the storage directions and discard date on the label, and use a new sterile needle and syringe for every dose. The FDA generally recommends discarding a multi-dose vial within 28 days of first use. If a dose looks wrong or you think you took too much, contact Poison Help at 1-800-222-1222 or call us at (682) 470-6080. Fainting, severe belly pain or vomiting you cannot stop needs emergency care.
Both medicines, sometimes called weight loss shots, copy gut hormones your body releases after a meal. They slow how fast your stomach empties and quiet hunger signals, so smaller portions feel like enough.
Semaglutide is a GLP-1 receptor agonist, which means it acts on one hormone receptor, GLP-1. Tirzepatide acts on two receptors, GIP and GLP-1. The NIDDK names both in its overview of prescription medicines for chronic weight management.
Neither medicine is the right pick for everyone. Your prescriber weighs your health history and other medicines. They also consider the side effects that worry you and what you have tried before. Some people start on one and later switch.
For drug-specific details, see our semaglutide weight loss program in Cleburne and our tirzepatide weight loss program in Cleburne.
Both trials enrolled adults with obesity, or with overweight plus a weight-related condition, who did not have diabetes. Each paired a weekly injection of the manufactured drug with lifestyle support.
| Semaglutide | Tirzepatide | |
|---|---|---|
| Trial | STEP 1, 68 weeks | SURMOUNT-1, 72 weeks |
| Dose studied | 2.4 mg once a week | 15 mg once a week (highest dose) |
| Average weight change | -14.9% (placebo -2.4%) | -20.9% (placebo -3.1%) |
| What it does not show | This result comes from the commercially manufactured semaglutide used in the trial. It is not evidence that an InjectCo compounded semaglutide preparation will produce the same result. | This result came from the manufactured tirzepatide studied in SURMOUNT-1. It does not establish equivalent effectiveness for a compounded tirzepatide preparation. |
| Published | New England Journal of Medicine, 2021 | New England Journal of Medicine, 2022 |
A dose changes only when the prescriber decides the change is appropriate. Staying on the same dose is a normal result of a monthly review, not a sign that something is wrong. Check-ins repeat every two weeks for as long as you are in the program.
Common side effects on the FDA-approved products include nausea, diarrhea, vomiting, constipation and belly pain. They tend to show up in the first weeks and after a dose increase. Compounded preparations have no FDA-approved label of their own, so we use the approved semaglutide and tirzepatide labels to explain the known risks of each medicine. Our guide to semaglutide results, timing and side effects covers how long they usually last.
Label warnings and precautions are different from contraindications. They are risks your prescriber weighs and watches for:
Other medicines. Tell your clinician about every prescription, over-the-counter medicine and supplement. Both medicines slow stomach emptying, which can change how some pills are absorbed. The tirzepatide label advises switching to a non-oral birth control method, or adding a barrier method, for 4 weeks after starting and after each dose increase. The semaglutide label has no such instruction.
Lab work is part of the Cleburne program and is completed before a first prescription. Its cost is included in the $425 monthly price. Which tests you need depends on your history, current medicines and conditions, so the list is not the same for every patient. Ask your clinician which tests were ordered, why, and where your sample will be collected.
The FDA-approved products are for adults with obesity, or with overweight plus at least one weight-related condition such as high blood pressure. In the main trials, that meant a BMI of 30 or higher, or 27 or higher with a condition. Dr. Allen reviews how our program applies those criteria.
A qualifying BMI opens the conversation. It does not guarantee a prescription. BMI does not tell fat from muscle, so the CDC advises reading it alongside blood pressure, cholesterol and an exam. On its own it does not decide the medicine, the form, the dose, or whether a compounded preparation is appropriate.
Weight regain occurred on average in the STEP 1 trial extension after treatment was withdrawn. The extension followed 327 adults for a year after they stopped semaglutide 2.4 mg and the trial’s lifestyle program. On average they regained about two-thirds of the weight they had lost (Diabetes, Obesity and Metabolism, 2022).
That is an average for one medicine in one trial group. It does not mean every patient regains the same amount, and it did not study tirzepatide or compounded preparations. What comes after treatment is decided with your prescriber, based on your medicine, your health and how you responded. Our article on avoiding weight gain after stopping semaglutide covers habits that help.
Illustration only. Not a prediction. The 20% figure is close to the 20.9% average with tirzepatide 15 mg in SURMOUNT-1; semaglutide 2.4 mg averaged 14.9% in STEP 1. Those percentages come from trials of commercially manufactured semaglutide and tirzepatide in specific populations. They do not establish outcomes for compounded medication or predict an individual patient’s result.
The Cleburne program is $425 a month. It covers the nurse consultation, program lab work, semaglutide or tirzepatide when it is prescribed, a check-in every two weeks and a monthly dose review. If one payment suits you better, $1,800 covers a 6 to 8 month program with the same inclusions.
We do not bill insurance. Many plans let you use HSA or FSA funds for eligible costs, but eligibility is set by your plan.
Approved patients can begin treatment the same day and pay over time instead of all at once.
How it works: apply online with CareCredit or Cherry in a few minutes, get a decision on the spot, then bring your approval to your appointment. Our team can help you compare options during your consultation and apply on the day if you prefer.
Terms and rates are set by the financing provider. Your nurse will walk you through your total cost, including any financing fee, before anything is booked.
Actual InjectCo patients, treated across our Texas clinics and shared with written consent. Individual results vary. These are not Cleburne-only results.
Use the arrows or swipe to browse the photos.
Cleburne Google reviews across services: our clinic has a 5.0 rating on Google from 70+ reviews. These quotes come from patients across all treatments, not weight loss specifically, and are shown as written.
Read every review on our Google Business Profile.
InjectCo MedSpa Cleburne is at 424 W Henderson St, in its own building on Business 67 in downtown Cleburne. It sits a short walk east of H-E-B and a few blocks west of the Johnson County Courthouse. The Cleburne Public Library is on the same street, and Cleburne is the county seat of Johnson County.
From Burleson or Joshua, SH 174 brings you into N Main St. From Keene and Alvarado, US 67 runs straight in, and Godley patients usually take SH 171. Consultations, check-ins and monthly reviews can happen by video, but lab collection cannot.
Every day, 8:00 AM to 8:00 PM
The consultation, program labs, your medication once prescribed, check-ins every two weeks with Paige, BSN, RN, and a monthly dose review with your prescriber.
You pay once and the program runs 6 to 8 months, including the same things as the monthly plan. If your plan might change partway through, ask us how the remaining months are handled before you pay.
It depends on your prescription. A plan may use an FDA-approved product or a compounded preparation, and your clinician tells you which before you start. Compounded preparations are not FDA-approved and skip the FDA’s premarket review.
Compounded prescriptions for Cleburne patients are dispensed by a 503B outsourcing facility. These facilities register with the FDA, but registration is not FDA approval or licensure of the facility or of its products.
The facility’s name is on your prescription label, and you can search it on the FDA’s registered outsourcing facilities list. For compounded semaglutide, ask whether it is made with semaglutide base; the FDA says it knows of no lawful basis for compounding with the sodium or acetate salt forms.
No. The FDA has not reviewed any compounded preparation for equivalence to an approved brand, and none is a generic version of one. Sharing an active ingredient name does not make it the same product, and trial results for the brands do not transfer to it.
Compounded concentrations differ between products, so the same number of syringe units can hold different amounts of medicine. Use only the syringe and instructions for your exact prescription, and ask Paige to check your technique at your next visit.
Side effects, appetite, hydration, bowel habits, eating patterns and your injection technique, plus weight and vitals at in-person visits. She reports to the prescriber and does not change doses.
No. The prescriber reviews your dose monthly, and a change happens only when your response and side effects support it. Staying on the same dose is a normal outcome.
A licensed prescriber working under Dr. Josh Allen, D.O., InjectCo’s Medical Director. Paige, BSN, RN, is a registered nurse and does not prescribe.
Your program is physician-supervised. Dr. Josh Allen, D.O., InjectCo’s Medical Director, oversees the protocols, and a licensed prescriber working under him reviews your history and labs and makes every prescribing decision. Your routine check-ins are with Paige, BSN, RN.
It depends on your history, medicines and conditions, so not every patient gets the same tests. Labs come before a first prescription and are included in the $425 a month.
STEP 1 and SURMOUNT-1 studied manufactured semaglutide 2.4 mg and tirzepatide in adults without diabetes, with lifestyle support. Their averages, 14.9% and 20.9% at the top tirzepatide dose, describe those groups. They do not predict one person’s result or apply to compounded preparations.
In the STEP 1 extension, people regained about two-thirds of their lost weight on average in the year after stopping semaglutide. Plan the next step with your prescriber before you stop.
Your consultation, check-ins every two weeks and monthly dose reviews can all happen by video. Lab collection cannot, and weight and vitals are recorded at in-person visits, so ask how your labs will be handled when you book. The clinic at 424 W Henderson St is open 8 AM to 8 PM every day.
We do not bill insurance; you pay the clinic directly. HSA or FSA money may cover eligible costs under your plan; your plan administrator can confirm. For costs outside our program, read our breakdown of semaglutide cost without insurance.
Yes. Patients come to our Cleburne clinic from Burleson, Joshua, Keene, Alvarado and other Johnson County towns for physician-supervised GLP-1 weight loss. We do not have a clinic in Burleson, and check-ins can be done by video. See our pages for med spa services near Burleson and near Joshua, and the drive-time list above.
Fill out the form and our Cleburne team will contact you. We will book your screening in the clinic or by video. Prefer to talk first? Call or text (682) 470-6080.
Both medicines need a prescription and a medical evaluation first. Compounded preparations are not FDA-approved; the FDA does not check their safety, effectiveness or quality before they reach patients (FDA).
Label contraindications: a personal or family history of medullary thyroid carcinoma, MEN 2, or a serious allergic reaction to the medicine. Weight loss is not recommended during pregnancy, and the labels say to stop when a pregnancy is recognized. Tell your prescriber about every condition and medicine you take.
Read the full prescribing information for semaglutide and tirzepatide.
If you have a reaction. Call or text the Cleburne clinic at (682) 470-6080, 8:00 AM to 8:00 PM every day. Get emergency care right away for severe belly pain that does not go away or vomiting that stops you keeping fluids down. Fainting and swelling of the face, lips or throat also need emergency care. To report a side effect to the FDA, use MedWatch.
Sources. Once-Weekly Semaglutide in Adults with Overweight or Obesity, NEJM 2021 · Tirzepatide Once Weekly for the Treatment of Obesity, NEJM 2022 · Weight regain after withdrawal of semaglutide: the STEP 1 trial extension, Diabetes, Obesity and Metabolism 2022 · FDA concerns with unapproved GLP-1 drugs · FDA compounding policies.
Clinical content contributed by InjectCo’s clinical team. Last medically reviewed September 20, 2026.
Medically reviewed by Dr. Josh Allen, D.O., Medical Director, InjectCo MedSpa.
*$50
OFF
*$50 OFF Your First Treatment
Expert
Injectors
FDA-
Approved
Products
Beautiful
Natural
Results
100+ 5-Star
Reviews
